Category Genetics

What a positive, negative, or APOE result actually means, who should deliver it, and how to decide who else in the family gets told.

Which Alzheimer's gene test applies depends on symptoms, family history, and drug eligibility — not age alone, and Medicare treats each differently.

APOE status, not the familial early-onset panel, is the genetic test that actually shapes Leqembi eligibility and monitoring after 65.

What a positive, negative, or inconclusive familial Alzheimer's result actually means after 65 — and which test you need instead.

Why a negative genetic result can still leave a family unsettled, and how to plan who hears it before cognition changes the answer.

Which Alzheimer's gene test actually fits your family history — and which one only matters if you're starting a specific drug.

ApoE genetic testing now decides amyloid-drug eligibility and monitoring intensity for patients over 65, not a diagnosis of Alzheimer's itself.

Why a three-gene panel built for early-onset Alzheimer's often tells people over 65 the least about their actual risk.

What the three-gene familial Alzheimer's panel finds, what it costs out of pocket, and why insurers cover it unevenly.

APOE genotyping, not the familial PSEN1/PSEN2/APP panel, is the test that can open or close the door to anti-amyloid drugs once symptoms progress.